Compare · ACON vs NTRA
ACON vs NTRA
Side-by-side comparison of Aclarion Inc. (ACON) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACON and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $46.13B, about 8181.1x ACON ($5.6M).
- Over the past year, ACON is down 68.9% and NTRA is up 105.1% - NTRA leads by 174.0 points.
- NTRA has been more active in the news (23 items in the past 4 weeks vs 4 for ACON).
- NTRA has more recent analyst coverage (25 ratings vs 0 for ACON).
- Company
- Aclarion Inc.
- Natera Inc.
- Price
- $2.26-3.83%
- $322.21+21.47%
- Market cap
- $5.6M
- $46.13B
- 1M return
- -22.34%
- +14.22%
- 1Y return
- -68.87%
- +105.11%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2015
- News (4w)
- 4
- 23
- Recent ratings
- 0
- 25
Aclarion Inc.
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest ACON
- SEC Form 10-Q filed by Aclarion Inc.
- Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology
- Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
- Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice
- SEC Form S-8 filed by Aclarion Inc.
- Aclarion Announces Texas Spine Care Center as New CLARITY Site
- Chief Strategy Officer Bond Ryan was granted 55,000 shares (SEC Form 4)
- Executive Chairman Thramann Jeffrey John was granted 100,000 shares (SEC Form 4)
- Chief Financial Officer Gould Gregory A was granted 50,000 shares (SEC Form 4)
- Director Sequira Amanda Mae was granted 20,000 shares (SEC Form 4)
Latest NTRA
- CO-FOUNDER Sheena Jonathan sold $2,888,325 worth of shares (9,150 units at $315.66) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 236,464 units (SEC Form 4)
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $641,800 worth of shares (2,000 units at $320.90) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Natera Inc.
- SEC Form 10-Q filed by Natera Inc.
- Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Natera Reports Second Quarter 2026 Financial Results
- PRESIDENT, CHIEF BUS. OFFICER Fesko John sold $79,057 worth of shares (295 units at $267.99) as part of a pre-agreed trading plan, decreasing direct ownership by 0.16% to 183,774 units (SEC Form 4) (for tax liability)
- CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold $216,030 worth of shares (795 units at $271.74) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 51,637 units (SEC Form 4) (withholding obligation)
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $905,627 worth of shares (3,410 units at $265.58) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 129,019 units (SEC Form 4) (tax withholding)
- CEO AND PRESIDENT Chapman Steven Leonard sold $819,431 worth of shares (3,076 units at $266.39) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 99,897 units (SEC Form 4) to cover taxes